1ROTH T, WRIGHT K P JR, WAISH J. Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double - blind, placebo - controlled study [ J ]. Sleep, 2006, 29 (3) : 335 -341.
3ROTH T, WALSH J K, KRYSTAL A, et al. An evaluation of the emcacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia [ J ]. Sleep Med, 2005, 6 ( 6 ) : 487 - 495.
4KRYSTAL A, WALSH J K, ROTH T, et al. Sustained efficacy and safety of eszopiclone over six months of nightly treatment: resutts of a randomized, placebo controlled study in adults with chro- nic insonmia[J]. Sleep, 2003, 26(7) : 793 -799.
5GIRAULT C, MUIR J F, MIHALTAN F, et al. Effects of repeated administration of zolpidem on sleep, diurnal and nocturnal respiratory function, vigilance, and physical performance in patients with COPD[J]. Chest, 1996, 110(5) : 1203 -1211.
6STAHL S M. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihista- mines [ J ]. CNS Spectr, 2008, 13 (12) : 1027 - 1038.
7RAJARATNAM S M, POLYMEROPOULOS M H, FISHER D M, et al. Melatonin agonist tasimelteon ( VEC - 162 ) for transient in- somnia after sleep time shift: two randomised controlled multi- centre trials[J]. Lancet, 2009, 373(9662) : 482 -491.
8NICKELSEN T, SAMEL A, VEJVODA M, et al. Chronobiotic effects of the melatonin agonist LY 156735 following a simulated 9h time shift : results of a placebo - controlled trial [ J ]. Chronobiol Int, 2002, 19(5) : 915 -936.
9National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13 - 15, 2005 [ J]. Sleep, 2005, 28(9): 1049- 1057.
1ROTH T. An overview of the report of the naitonal commission on sleep disorders research[J]. Eur Psychiat, 1995,10( Suppl 3 ) :109s- l13s.
2BALTER MB, UHLENHUTH EH. The beneficial and adverse effects of hypnotics [ J ], J Clin Psychiatry, 1991,52 ( Suppl ) :S16 - S23.
3WALSH JK, ENGELHARDT CL. The direct economic costs of insomnia in the United States for 1995 [ J]. Sleep, 1999,22( Suppl 2) :5386 - $393.
4ZORUMSKI CF, ISENBERG KE. Insights into the structure and function of GABA-benzodiazepine receptors: Ion channels and psychiatry [ J ]. Am J Psychiatry, 1991,148 ( 2 ) : 162 - 173.
5LUDDENS H, KORPI ER. Biological functions of GABA A benzodiazepine receptor heterogeneity [ J ]. J Psychiatry Res , 1995,29(2) :77 -94.
6PAPADOPOULOS V. In search of the function of the peripheral-type benzodiazepine receptor [ J ]. Endocrine Res, 2004, 30 ( 4 ) :677 - 684.
7RUSH CR, GRIFFITHS RR. Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers[ J].J Clin Psyhopharmacol, 1996,16( 1 ) :146 -157.
8JUDD LL, ELLINWOOD E, MCADAMS LA. Cognitive performance and mood in patients with chronicinsomnia during 14-day use of flurazepam and midazolam [ J ] . J Clia Psychopharmacol ,1990,10(4 ) :56S - 67S.
9NOWELL P, MAZUMDAR S, BUYSSE D, et al. Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy [ J ]. JAMA, 1997,278 ( 6 ) :2170.
10DAVIES M, GLEN NJ, DERBY JMC, et al. Characterization of the interaction of zopiclone with γ-aminobutyric acid type A receptors[J]. Mol Pharmacol,2000,58 (4) :756 - 762.
